Please select the option that best describes you:
What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?
As opposed to Atezolizumab/Bevacizumab or Durvalumab/Tremelimumab.
Answer from: Medical Oncologist at Academic Institution
Great question! CheckMate 9DW with the combination IPI3/NIVO1 compared to sorafenib/lenvatinib (85% were lenvatinib in the control arm) significantly improved OS (23.7 months vs 20.6 months, HR 0.79, P-value 0.018), response 36% vs 13% (P-value <0.0001). Based on these data, it received FDA appro...
Sign in or Register to read more